ALNY

NASDAQ HEALTHCARE

Alnylam Pharmaceuticals Inc

$219.89

$0.17 (+0.08%)

Live quote

52w: $197.81 – $495.55

Loading chart…

P/E Ratio93.71

P/B Ratio21.71

EV/EBITDA—

Debt/Equity—

ROE23.17%

ROIC—

Revenue Growth65.19%

Gross Margin—

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.

Own ALNY? Track it here.

Create a free account to add ALNY to a portfolio and watch your P/L update in real time.

Custom screens, valuation models and backtesting are coming to Pro.

Create a free account